Suppr超能文献

一种基于新型临床列线图的前列腺活检策略可减少高危患者所需的活检核心数量。

A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients.

机构信息

State Key Laboratory of Reproductive Medicine, Department of Urology, First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd, Nanjing 210029, China.

出版信息

BMC Urol. 2014 Jan 11;14:8. doi: 10.1186/1471-2490-14-8.

Abstract

BACKGROUND

The nomograms used for prostate cancer risk assessment in Western countries are not directly applicable to Chinese males; consequently, we have developed a new model to evaluate the risk of them developing this disease.

METHODS

A total of 1104 patients who had undergone trans-rectal ultrasound (TRUS)-guided 12 + 1-core prostate biopsy were retrospectively evaluated in the first stage of the study. Age, prostate-specific antigen (PSA), the free/total PSA ratio (f/t), digital rectal examination (DRE) findings, the presence of a hypoechoic mass revealed using ultrasound, ultrasonic detection of microcalcifications, prostate volume (PV) and PSA density were considered as predictive factors. Multiple logistic regression analysis involving a backward elimination selection procedure was used to select independent predictors. We compared positive rates regarding 6-core and 12-core biopsy schemes at different risk levels. In the second stage of the study, 238 cases were evaluated using our nomogram. In higher risk patients, we employed a 6 + 1 core biopsy. Positive rates in the first and second stages of the study were compared.

RESULTS

Age, the baseline median natural logarithm of PSA (Ln[PSA]), Ln(PV), f/t, rate of abnormal DRE findings and rate of hypoechoic masses detected using TRUS were the factors that were finally submitted into our nomogram. A significantly greater area under the receiver-operating characteristic curve was obtained for the nomogram than for PSA level alone (0.853 vs. 0.761). A cancer probability cutoff value of 0.5 suggested no significant difference between the 6-core and 12-core biopsy schemes at higher risk levels. In the second stage of the study we verified that in patients with a cancer probability cutoff value >0.5, a 6 + 1-core biopsy could be used without a reduction in the positive detection rate, and significantly reducing the number of biopsy cores required.

CONCLUSIONS

A nomogram based on data from Chinese males was developed to predict the positive detection rate, ratio of positive cores and Gleason score at each risk level. According to this nomogram, a reasonable biopsy strategy could be constituted to reduce the number of biopsy cores required in subjects at high risk.

摘要

背景

西方国家用于前列腺癌风险评估的列线图不能直接应用于中国男性;因此,我们开发了一种新的模型来评估他们患这种疾病的风险。

方法

在研究的第一阶段,我们回顾性地评估了 1104 名接受经直肠超声(TRUS)引导的 12+1 芯前列腺活检的患者。年龄、前列腺特异性抗原(PSA)、游离/总 PSA 比值(f/t)、直肠指诊(DRE)结果、超声显示的低回声肿块的存在、超声检测微钙化、前列腺体积(PV)和 PSA 密度被认为是预测因素。采用向后消除选择程序的多因素逻辑回归分析来选择独立的预测因子。我们比较了不同风险水平下 6 芯和 12 芯活检方案的阳性率。在研究的第二阶段,我们使用我们的列线图评估了 238 例病例。在高危患者中,我们采用了 6+1 芯活检。比较了研究第一和第二阶段的阳性率。

结果

年龄、基线中位自然对数 PSA(Ln[PSA])、Ln(PV)、f/t、DRE 异常率和 TRUS 检测到的低回声肿块率是最终纳入我们列线图的因素。列线图的受试者工作特征曲线下面积明显大于 PSA 水平单独(0.853 对 0.761)。当癌症概率截断值为 0.5 时,高危水平下 6 芯和 12 芯活检方案之间无显著差异。在研究的第二阶段,我们验证了在癌症概率截断值>0.5 的患者中,6+1 芯活检可以在不降低阳性检出率的情况下使用,并显著减少活检芯的数量。

结论

基于中国男性数据开发了一种列线图,用于预测每个风险水平的阳性检出率、阳性核心比例和 Gleason 评分。根据这个列线图,可以制定合理的活检策略,减少高危人群所需的活检芯数量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/60df/3893548/3668bba8980d/1471-2490-14-8-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验